BEST AVAILABLE COPY



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

	Address :	COMMISSIONER OF PATENTS AND TRADEMARKS
		Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED	INVENTOR		ATTORNEY DOCKET NO
<u> </u>	9-109/05/901	PANICALI		D .	ABT87-Ó1
					EXAMINER
RONALD I	EISENSTÈIN			- ZITOMER,	5
	STEIN, ROBERTS	1. CHOLIMAN			
130 WATER	STREET	« COSHINNIA		ART UNIT	PAPER NUMBER
BOSTON, MA				187	19'
•				187	18
				DATE MAILED:	10/01/91
This is a communication in COMMISSIONER OF PAT	rom the examiner in charge of y FENTS AND TRADEMARKS	our application.	÷		
		•			
. This application has b	een examined r Res	ponsive to communication file	ed on		This action is made final.
A shortened statutory peri	od for response to this acti	on is set to expire	month(s),<	35 U.S.C. 133	THE CAME OF LIES SECON.
Failure to respond within t	ne period for response will	cause the application to bec	ome and one	00 0.0.0.	
Part I THE FOLLOWING	G ATTACHMENT(S) ARE	PART OF THIS ACTION:			
		,	. — n	e Patent Drawing, I	PTC-948
	rences Cited by Examiner,	1 10-002.			oplication, Form PTO-152
3. Notice of Art C	Cited by Applicant, PTO-14	49.7	" = ''''	и шоппы Раселт Р	ppication, runn r ro-rue
5. Information on	How to Effect Drawing Ch	anges, PTO-1474.	6		
Part II SUMMARY OF	ACTION .		•		
1. K Claims /- 3	35	<u> </u>		· ;	are pending in the applica
Of the	above, claims		<u> </u>		re withdrawn from considers
2. Claims	·			<u></u>	have been cancelled.
s. 🔲 Claims			-		are allowed.
4. Claims			<u>.</u>		are rejected.
	•				are objected to.
6. Claims 1-3				e subject to restric	tion or election requirement.
		mal drawings under 37 C.F.F			
		·			
·	gs are required in respons		. •		
	or substitute drawings have	re been received on (see explanation or Notice re	Patent Drawing.		er 37 C.F.R. 1.84 these drav
	. additional or substitute sh	eet(s) of drawings, filed on	-	has (have) been	approved by the
examiner:	disapproved by the exami	ner (see explanation).			·
11. The proposed	drawing correction, filed	oo waa sa ka	beën 🗀 approv	ved; 🔲 disapprovi	ed (see explanation).
4 12 Acknowledgen	nent is made of the claim fo	or priority under -U.S.C. 119.	The certified co		
□ been filed	in parent application, serial	noi	filed on		
a 13. Since this app	lication apppears to be in o	condition for allowance excep	t for formal matte	ers, prosecution as	to the merits is closed in
accordance,w	ith the practice under Ex pa	arte Quayle, 1935 C.D. 11; 4	53 O.G. 213.		*
A STATE OF THE STA			•		.
- 14 U Other					
			•	-	*
. H		• •	•	•	;
	Ý		.:	;	
Sand Shipping	The state of the s				w 500 - 20
		**************************************	· 5 7 - 7 - 7		Section of the section of
SOME STATE OF THE	The second second	· YVe s CT	•	•	- white
		119	•	*	

Serial No. 579,269 Art Unit 187

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- I. Claims 1-14 and 27-31, drawn to a recombinant pox virus and vectors therefor, classified in Class 435, subclasses 252.3 and 320.1:
- II. Claims 15-24, drawn to methods for producing therapeutic pox virus antigens and antibodies, classified in Class 514, subclass 44;
- III. Claim 25, drawn to a method for producing a monoclonal antibody, classified in Class 435, subclass 70.2;
- IV. Claim 26, drawn to a method for therapeutic administration of antibody, classified in Class 514, subclass 21.

Invention I is related to Inventions II and III as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case the processes for using can be practiced with a natural pox virus.

Inventions II and III are unrelated to Invention IV and are distinct as different processes wherein the products of II and III may be used in IV and the process of Invention IV can be

Serial No. 579,269 Art Unit 187

practiced with different products such as antibodies to naturally occurring pox virus.

Inventions I and IV are unrelated as being drawn to DNA and to a process using protein, respectively, wherein DNA and protein are chemically distinct compounds and the protein can be used in a different way, for example, as a tissue-specific carrier for a therapeutic compound.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classifications restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephanie Zitomer whose telephone number is (703) 308-3881. Any inquiry of a general nature or relating to the status of this application

Serial No. 579,269 Art Unit 187

should be directed to the Group 180 receptionist at (703) 308-0196.

SUZ

Stephanie W. Zitomer, Ph.D. September 30, 1991

ROBERT A. WAX
SUPERVISORY PATENT EXAMINER

ART UNIT 187